Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.
Virus neutralizing antibodies in SIV and type D vaccinated macaques, and in animals infected with SIV/Mne.
Symp Nonhum Primate Models AIDS. 1990 Nov 28-30;8:46 (abstract no. 30). Unique Identifier : AIDSLINE PRIM8/900030 Benveniste R; Mann D; Kuller L; Morton W; Hu SL; Eddy G; Shafferman A; Lewis M; National Cancer Institute and Southern Research Institute,; Frederick, MD
Abstract:
An EBV transformed human cell line (AA-2) had previously been shown by us to be very sensitive to the replication of SIV's isolated from mangabeys, African green monkeys and macaques, as well as to HIV-1 and HIV-2. Multiple single-cell clones have now been obtained that differ markedly in their ability to replicate these viruses. One of these, AA-2 CL 1, expresses the B cell markers CD20 and CD 21, the T cell marker CD4 (but not CD2, CD3, or CD8), as well as HLA-DR. The sensitivity of the AA-2 CL 1 cell line is such that stocks of SIV/Mne exhibit higher titers in vitro using this cell line than can be shown in animal titration studies. A microtiter syncytial cell reduction assay using these cells has been developed and used to assay for virus neutralizing activity in serum samples from 3 M. mulatta, 11 M. nemestrina, and 10 M. fascicularis involved in SIV/Mne infectivity studies. Neutralization titers, when present, were found to peak approximately 25% of the way into the disease course. No macaque (all of which died with opportunistic infections and CD4 depletion) had detectable neutralizing activity in serum samples obtained near the time of death. This assay has also identified the presence of neutralizing activity in three rhesus that had been immunized with four small peptides from conserved regions of the SIV gp120 and transmembrane proteins. The extent of neutralizing activity detected in the sera correlated well with the ability of these animals to resist a challenge with 100 TCID of SIV/Mne. Similar assays employing single-cell clones of Raji cells have been used to detect neutralizing activity in macaques immunized with live vaccinia virus recombined with and expressing the envelope proteins of SRV-2/Washington. This vaccine protects macaques against a large intravenous challenge dose (10(6) TCID of SRV-2), and shows evidence of neutralizing in vitro other serotypes of type D viruses.
Keywords: Animal Antibodies, Viral/*IMMUNOLOGY Antigens, Differentiation, B-Lymphocyte/IMMUNOLOGY B-Lymphocytes/IMMUNOLOGY Cell Line Cercopithecus aethiops Complement 3d/IMMUNOLOGY Cytopathogenic Effect, Viral CD4-Positive T-Lymphocytes/IMMUNOLOGY HIV Envelope Protein gp120/IMMUNOLOGY Macaca fascicularis Macaca nemestrina Neutralization Tests Receptors, Complement/IMMUNOLOGY Receptors, Virus/IMMUNOLOGY Sensitivity and Specificity Simian Acquired Immunodeficiency Syndrome/*PREVENTION & CONTROL SIV/GROWTH & DEVELOPMENT/*IMMUNOLOGY *Vaccination Vaccinia Virus/IMMUNOLOGY ABSTRACT 910730
M9170964
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1991. The state of the art may have changed since the publication date.
